Contributors: Guerra-Librero,A; Fernandez-Gil,BI; Florido,J; Martinez-Ruiz,L; Rodríguez-Santana,C; Shen,YQ; López-Rodríguez,A; Rusanova,I; Acuña-Castroviejo,D; Escames,G Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain. Guerra-Librero,A; Escames,G CIBERFES, Ibs.Granada, San Cecilio University Hospital, Granada, Spain. Florido,J; Escames,G Department of Physiology, Faculty of Medicine, University of Granada, Granada, Spain. García-Verdugo,JM Cavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia, Valencia, Spain. Rusanova,I Department of Biochemistry and Molecular Biology I, Faculty of Science, University of Granada,Granada, Spain. Quiñones-Hinojosa,A Department of Neurologic Surgery, Mayo Clinic, Jacksonville, USA. Marruecos,J Institut Català d’Oncologia (ICO), Hospital Universitari Dr. Josep Trueta, Girona, Spain. De Haro,T UGC de Laboratorios Clínicos, Hospital Universitario San Cecilio, Granada, Spain.; This study was funded by grants from the Ministerio de Economia, Industria y Competi tividad y por el Fondo de Desarrollo Regional FEDER, Spain n◦ SAF2013-49019, SAF2017-85903-P, and from the Consejería de Innovación, Ciencia y Empresa, Junta de Andalucía (P07- CTS- 03135, P10- CTS- 5784, and CTS- 101), Spain. J.F. and L.M. have FPU fellowships from the Ministerio de Educación Cultura y Deporte, Spain. C.R.S. was a schorlarship holder from the Plan Propio de Investigación of the University of Granada
نبذة مختصرة : Metabolic reprogramming, which is characteristic of cancer cells that rapidly adapt to the hypoxic microenvironment and is crucial for tumor growth and metastasis, is recognized as one of the major mechanisms underlying therapeutic resistance. Mitochondria, which are directly involved in metabolic reprogramming, are used to design novel mitochondria-targeted anticancer agents. Despite being targeted by melatonin, the functional role of mitochondria in melatonin's oncostatic activity remains unclear. In this study, we aim to investigate the role of melatonin in mitochondrial metabolism and its functional consequences in head and neck cancer. We analyzed the effects of melatonin on head and neck squamous cell carcinoma (HNSCC) cell lines (Cal-27 and SCC-9), which were treated with 100, 500, and 1500 µM of melatonin for 1, 3, and 5 days, and found a connection between a change of metabolism following melatonin treatment and its effects on mitochondria. Our results demonstrate that melatonin induces a shift to an aerobic mitochondrial metabolism that is associated with changes in mitochondrial morphology, function, fusion, and fission in HNSCC. We found that melatonin increases oxidative phosphorylation (OXPHOS) and inhibits glycolysis in HNSCC, resulting in increased ROS production, apoptosis, and mitophagy, and decreased cell proliferation. Our findings highlight new molecular pathways involved in melatonin's oncostatic activity, suggesting that it could act as an adjuvant agent in a potential therapy for cancer patients. We also found that high doses of melatonin, such as those used in this study for its cytotoxic impact on HNSCC cells, might lead to additional effects through melatonin receptors. ; Yes
Processing Request
No Comments.